About ZEJULA (niraparib)
ZEJULA Inhibits PARP1 and PARP2, Leading to Cancer Cell Death in Pre-Clinical Studies1
ZEJULA inhibits PARP1 and PARP2, leading to cancer cell death in preclinical studies.4
The clinical significance of in vitro studies is unknown. Mechanism of action statements are not meant to imply clinical efficacy.
PARP, poly (ADP-ribose) polymerase.
BRCA1/2, breast cancer susceptibility genes 1 and 2.
Preclinical studies suggest the activity of PARP inhibitors depends on tumor exposure and subsequent PARP1/2 inhibition.5
- Tumor cells carrying a BRCA mutation have been shown to be significantly more sensitive to PARP inhibition than tumors that do not carry a BRCA mutation6
- It is hypothesized that in tumors without a BRCA mutation, PARP inhibitors may need to achieve higher tumor concentrations for effect6